Delivra-Celecoxib 8% Cream and Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-23

Study Completion Date

2019-10-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The observation of the clinical use of the Delivra Celecoxib cream (8%) in the treatment of osteoarthritis of the knee. Observations will be made over 12 weeks of treatment. Evaluations include: pain, functionality and patients global assessment of disease. Patients will self administer treatment as prescribed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Delivra-Celecoxib 8% Cream and Osteoarthritis

NCT03698916

Osteoarthritis, Knee

TERMINATED

Delivra Joint Health Cream In The Treatment Of Pain Caused By Osteoarthritis Of The Knee

NCT02193711

Osteoarthritis

COMPLETED PHASE3

Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial

NCT04718649

Osteoarthritis

UNKNOWN NA

Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee

NCT00137410

Osteoarthritis,Knee

COMPLETED PHASE3

Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)

NCT00630929

Osteoarthritis, Knee

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis, Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Patients with primary osteoarthritis (with radiological evidence) of the knees who have been prescribed Del-Cel.
* On stable pain therapy with an oral or topical NSAID or acetaminophen.
* Able to read and understand English to answer pain assessment questions independently.
* Willing and able to fulfill the requirements of the study, including complete scheduled follow-up phone visits.

Exclusion Criteria

* Inability to adequately read and understand English as required to complete study assessments and comply with the protocol.
* Current recreational or medicinal use of cannabis within 4 weeks of study initiation.
* Participants with a lifetime history of cannabis use disorder or other substance use disorders (except tobacco use disorder) will be excluded.
* Participants with a lifetime history of daily cannabis use will be excluded.
* Dose changes of concomitant medication will not be permitted during the study period.
* Pregnant women, lactating women, and women of childbearing potential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months), or women who are planning on becoming pregnant.
* Diagnosis of any of the following mental disorders as defined by the DSM-5: a lifetime history of schizophrenia or any other psychosis, organic medical disorders, bipolar disorder. Entry of patients with obsessive compulsive disorder or post- traumatic stress disorder will be permitted if the anxiety disorder is judged to be the predominant disorder, in order to increase accrual of a clinically relevant sample.
* Major depression will be allowed if not severe (Montgomery Åsberg Depression Rating Scale-MADRS27≥ 25). Patients with significant suicidal ideation (MADRS item 10 score \> 3) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.
* Participants with a family history of schizophrenia spectrum or bipolar disorder will be excluded.
* Participants who have a history of adverse reactions to cannabis will be excluded.
* Known allergy to any of the ingredients in the Delivra base.
* Use of Rimonabant (SR141716) within three weeks of enrollment and/or planned use for the duration of the study participation\[27\].
* Use of 5-HT1A receptor antagonists (SSRI inhibitors) within three weeks of enrollment and/or planned use for the duration of the study participation, e.g.: Pindolol, Lecozotan, Brexpiprazole, etc.

Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No